225Ac-PSMA-Trillium (BAY 3563254)

· Bayer

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for 225Ac-PSMA-Trillium (BAY 3563254), covering 2026-03-31 to 2026-03-31. Get the full timeline:

Most recent: Clinical Trial Update: First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) [Phase 1]

See pricing